{"classes":[{"categories":[{"measurements":[{"comment":"Too few events have occurred to obtain a median or a 95% CI.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"}],"units":"Participants"}],"description":"Progression-free survival is defined as the time from registration to the time of progression or death. This study will not use RECIST criteria to evaluate response or progression. The patients enrolled will have non-measurable disease on imaging and response will be evaluated with biopsy or cytology. Progression is defined as progression in T stage, N stage or M stage both clinically or radiologically. Histological confirmation of metastatic disease is at the discretion of the treating provider. The median time will be estimated using the method of Kaplan-Meier.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received avelumab IV over 60 minutes every 14 days for a total of 10 courses in the absence of disease progression or unacceptable toxicity. Beginning 29 days after the first dose of avelumab, participants received 35 mg/m\\^2/day cisplatin IV starting on day 1 of courses 3-5 for up to 6 weeks in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Avelumab and Cisplatin IV"}],"paramType":"MEDIAN","populationDescription":"All patients who registered and were treated are included in this analysis.","reportingStatus":"POSTED","timeFrame":"From registration to time of first documentation of progression or death from any cause, assessed up to 12 months","title":"Progression-free Survival","type":"SECONDARY","unitOfMeasure":"years"}